OC 103 - Oyster Point Pharmaceuticals
Alternative Names: OC-103 (AAV-DAO); OC-103 - Oyster Point Pharmaceuticals; OC-103 AAV-DAOLatest Information Update: 13 Jan 2023
At a glance
- Originator Oyster Point Pharmaceuticals
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Keratoconjunctivitis
Most Recent Events
- 03 Jan 2023 Oyster Point Pharmaceuticals has been acquired by Viatris Inc
- 04 Nov 2022 Preclinical trials in Keratoconjunctivitis in USA (Ophthalmic, Injection) (Oyster Point Pharmaceuticals pipeline, November 2022)
- 04 Nov 2022 Oyster Point Pharmaceuticals intends to hold pre-IND meetings with the US FDA in the second half of 2022 for OC 103 (Oyster Point Pharmaceuticals pipeline, November 2022)